Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 27, 2020
Daily News
October 27, 2020
- Pharma’s Half-Year Earnings Season in Full Swing from This Week
October 27, 2020
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
- Japan Trade Groups Step Up Lobbying Campaigns as Diet Convenes, Renew Call for “Cautious Approach” to Off-Year Re-Pricing
October 27, 2020
- Reform Minister Asks MHLW to Facilitate Global Launch of Japan-Originated Medical Software Programs
October 27, 2020
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- NC-6004-Keytruda Combo Racks Up Positive US PIIa Results for Head and Neck Cancer: NanoCarrier
October 27, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…